TL;DR
This umbrella review synthesizes 47 meta-analyses to confirm that Tranexamic Acid (TXA) is a highly effective and generally safe tool for reducing blood loss and transfusion rates across a wide range of surgeries. While it offers significant hemostatic benefits and even shortens hospital stays, the study highlights a specific risk of seizures in cardiac surgery and provides tailored dosage recommendations for various clinical scenarios.
What Problem Does This Paper Address?
Hemorrhage remains a leading cause of death and complication in surgical settings. While allogeneic blood transfusions are a standard response, they carry risks of immune reactions and infections. Tranexamic Acid (TXA)—a synthetic lysine analogue that prevents blood clots from breaking down—has emerged as a popular, cost-effective alternative for maintaining hemostasis.
However, the clinical application of TXA has been inconsistent. Its efficacy and safety profile vary across different types of surgery (e.g., orthopedic vs. cardiac vs. cerebral), and clinicians often lack unified, evidence-based guidelines for dosage and administration. This paper seeks to provide a "state-of-the-art" umbrella review to resolve these controversies and offer clear clinical recommendations.
Methods
The authors performed an umbrella review, which is essentially a "review of reviews." They systematically searched Medline, Embase, Web of Science, and the Cochrane Library, identifying 47 high-quality meta-analyses.
To ensure the reliability of their conclusions, they employed several rigorous methodological tools:
- AMSTAR 2: Used to assess the methodological quality of the included systematic reviews.
- GRADE: Used to evaluate the quality of evidence for specific outcomes (e.g., blood loss, mortality).
- Corrected Covered Area (CCA): A specialized calculation used to manage "overlapping" reviews, ensuring that primary studies included in multiple meta-analyses weren't double-counted, which could skew the results.
Datasets
The study did not generate a new primary dataset but rather distilled data from 47 meta-analyses covering 319 unique outcomes. These outcomes were drawn from hundreds of randomized controlled trials (RCTs) involving tens of thousands of patients across various surgical specialties, including joint replacement, spine surgery, cardiac surgery, and obstetrics.
Key Insights and Ideas
- Universal Hemostatic Effect: TXA isn't just effective for trauma; it demonstrates significant benefits across almost all major surgical categories, reducing total blood loss and the need for emergency transfusions.
- The Seizure Caveat: One of the most critical "aha" moments is the confirmation that TXA is a risk factor for seizures in cardiac surgery. The authors note that high-dose TXA can increase seizure risk by nearly five times, likely due to its interference with inhibitory GABAergic neurotransmission in the brain.
- Safety vs. Fear: A common clinical concern is that TXA might increase the risk of "vascular adverse events" like deep vein thrombosis (DVT), stroke, or myocardial infarction. This review found that TXA generally does not increase these risks, positioning it as a safe choice for most patients.
- Efficiency Gains: Beyond just saving blood, TXA use was associated with shorter operative times and reduced lengths of hospital stay, suggesting that better blood management leads to faster overall recovery.
Key Results
- Quality of Evidence: 44 of the 47 meta-analyses were rated as "high" quality via AMSTAR 2.
- Blood Loss Reduction: In major orthopedic surgeries like total hip arthroplasty (THA), TXA reduced blood loss by an average of 389.14 ml.
- Transfusion Rates: TXA reduced the transfusion rate in major orthopedic surgery by 49% (RR 0.51) and in cardiac surgery by 29% (RR 0.71).
- Re-operation: In cardiac surgery, TXA was shown to avert 38% of re-operations caused by excessive bleeding.
- Dosage Recommendations: The authors provide a specific table (Table 5) of recommended dosages, such as 1–1.5 g IV combined with 1–3 g topical for joint replacements and 10–15 mg/kg IV for spinal surgery.
Limitations and Future Work
The primary limitation acknowledged by the authors is the heterogeneity of the experimental designs. Because different trials used different dosages and administration routes (oral, IV, topical), it is difficult to recommend a single "unified" dosage for all surgeries.
Additionally, the review was limited to studies published in English and Chinese, potentially introducing language bias. Some meta-analyses also excluded patients with pre-existing renal or cardiovascular issues, meaning the results might not perfectly generalize to the highest-risk patient populations. Future research should focus on refining the "optimal" dose for specific sub-specialties and investigating the long-term outcomes of TXA-induced seizures.
Summary updated